The U.S. Food and Drug Administration (FDA) has issued the final ICH E6(R3) Good Clinical Practice (GCP) guidance, establishing an updated global standard for the design, conduct, oversight, documentation and reporting of clinical trials.
This update represents a major step in the evolution of GCP. It reinforces participant safety and data reliability, promotes risk-based trial management, and increases flexibility to accommodate decentralized trials, digital tools and real-world data in a fast-changing technological and scientific landscape.
Key updates in ICH E6(R3)
- Increased flexibility to support a broader range of modern trial designs, data sources and technologies.
- Advancement of quality-by-design and risk-based quality management for trial conduct and oversight.
- Clarification of sponsor and investigator responsibilities.
- Emphasis on proportionality, relevance and critical thinking across the clinical trial lifecycle.
Aligned with global harmonization goals, E6(R3) seeks to ensure clinical trial practices evolve alongside innovation while safeguarding participant welfare and the integrity of trial data.
How Asphalion can help
At Asphalion, we are ready to support your clinical development programs through this regulatory transition. Our services include regulatory strategy, operational alignment with E6(R3) expectations, and implementation support for decentralized and digitally enabled trial approaches.
Contact us to discuss how we can help adapt your ongoing or upcoming trials to the new ICH E6(R3) framework: [email protected]
Learn more: FDA E6(R3) Guidance – Final
